ATG-201 / Antengene - LARVOL DELTA

ATG-201, a novel T-cell engager (TCE) effectively depletes B cells with reduced risk of CRS for the treatment of B cell malignancies and B cell related autoimmune diseases (AACR 2025) - "ATG-201 demonstrates CD19-dependent CD3 binding and activation, inducing effective B cell depletion in vitro and in vivo with low cytokine release, which provides potential for the treatment of B cell malignancies and B cell related autoimmune diseases."

Hematological Malignancies • Lymphoma • Oncology • CD34 • CD8

ATG-201, a novel T-cell engager (TCE) effectively depletes B cells with reduced risk of CRS for the treatment of B cell malignancies and B cell related autoimmune diseases (PRNewswire) - "ATG-201 demonstrated high affinity binding to CD19, limited T cell binding before CD19 crosslinking, highly potent CD19-dependent T cell cytotoxicity against CD19+ B cells, as well as enhanced naïve B cell depletion with reduced cytokine release compared to clinical benchmarks. In lymphoma models, the study observed potent in vivo efficacy with reduced cytokine release. In CD34+ hematopoietic stem cells humanized mice, ATG-201 was able to induce complete B cell depletion with reduced cytokine release."

Preclinical • Hematological Malignancies • Lymphoma

Antengene to Present Results From Four Cutting Edge Preclinical Studies at AACR 2025 with Focuses Including AnTenGager TCEs and Synthetic Lethality (PRNewswire) - "Results: Compared to benchmark TCEs, ATG-201 demonstrated stronger naïve B cell depletion activity with much lower cytokine release in vitro. ATG-201 showed potent anti-lymphoma activity in PBMC-humanized subcutaneous Raji xenograft model with significant augment of infiltrated CD8+ T cells in tumor microenvironment and limited proinflammatory cytokines detected in plasma. Single dose ATG-201 completely and deeply depleted B cells in blood, bone marrow and spleen of CD34+ cells humanized mice. ATG-201 demonstrated potent efficacy in mouse systemic lupus erythematosus model, inhibiting the lymph node swelling and auto-antibody producing."

New trial • Preclinical • Hematological Malignancies • Immunology • Multiple Sclerosis • Systemic Lupus Erythematosus

Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials with Accelerating Multi-market Revenue Ramp Up (PRNewswire) - "ATG-201, a CD19 x CD3 TCE 2.0 developed on the AnTenGage TCE 2.0, is poised to enter clinical development in the second half of 2025."

New trial • Immunology

BUSINESS PROGRESS AND UPDATE (HKEXnews) - "The Company’s lead TCE program, ATG-201, is a next-generation TCE targeting CD19 x CD3 for B Cell-related autoimmune diseases, which has completed upstream chemical manufacturing and control (CMC) development and is expected to finalize investigational new drug (IND) preparation in Q3 2025."

IND • Immunology

ATG-201, a novel '2+1' CD19-targeted T-cell engager (TCE) for the treatment of B cell malignancies and B cell related autoimmune diseases (SITC 2024) - "F. B cell depletion and concentration of the indicated cytokines (G) in the supernatant of isolated human PBMC incubated with ATG-201 or Benchmarks (20 nM) for 48 hours"

Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

ATG-201, a novel '2+1' CD19-targeted T-cell engager (TCE) for the treatment of B cell malignancies and B cell related autoimmune diseases (SITC 2024) - "F. B cell depletion and concentration of the indicated cytokines (G) in the supernatant of isolated human PBMC incubated with ATG-201 or Benchmarks (20 nM) for 48 hours"

Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

Title: ATG-201, a novel "2+1" CD19-targeted T-cell Engager (TCE) for the treatment of B cell malignancies and B cell related autoimmune diseases (PRNewswire) - "Antengene Corporation Limited...announced that it will present results from...programs at the 2024 Society for Immunotherapy of Cancer Annual Meeting (SITC 2024)....Abstract Number: 1067:...ATG-201 binds to CD19+ cells with high affinity, limiting CD3 binding and T cell activation before CD19 crosslinking, reducing the risk of CRS. It demonstrated strong B-cell depletion and anti-lymphoma efficacy in preclinical studies with lower cytokine release compared to other benchmarks. ATG-201 demonstrated deep and durable depletion of tissue resident B cells in mice and showed potent in vivo efficacy in models for autoimmune diseases (MS, SLE)."

Preclinical • Hematological Malignancies • Immunology • Multiple Sclerosis • Systemic Lupus Erythematosus

Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting (PRNewswire) - "Antengene Corporation Limited...announced that it will present three programs at the 2024 Society of Immunology in Cancer Annual Meeting (SITC 2024) to be held in Houston from November 6-10, 2024."

Preclinical • Immunology

Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization (PRNewswire) - P1 | N=48 | PERFORM (NCT06028373) | Sponsor: Antengene Biologics Limited | "ATG-031 is the first-in-class humanized anti-CD24 monoclonal antibody to enter clinical trials for cancer in the U.S...In the Phase I PERFORM study, 19 late-stage cancer patients have been treated with early low doses in the dose escalation segment, with no dose-limiting toxicities (DLTs) observed. Observations include stable disease (SD), objective tumor shrinkage, and clinical improvements among enrolled patients. The company targets a Phase I data readout in the first half of 2025....The development of preclinical candidates, including ATG-042, a selective PRMT5 inhibitor targeting MTAP-null tumors, and ATG-201, a CD19 x CD3 T-cell engager, is ongoing."

P1 data • Preclinical • Hematological Malignancies • Oncology • Solid Tumor